Related Experiment Videos
[Pentasa (mesalazine) and pregnancy]
A P Jonville-Bera1, C Soyez, A Fignon
1Service de Pharmacologie clinique, CHRU Bretonneau, Tours.
Therapie
|September 1, 1994
Summary
Mesalazine (Pentasa) use during pregnancy for inflammatory bowel disease resulted in 9 healthy births from 11 pregnancies. Further research is needed to confirm these findings on mesalazine safety in pregnancy.
Area of Science:
- Obstetrics and Gynecology
- Gastroenterology
- Pharmacology
Context:
- Inflammatory bowel disease (IBD) management during pregnancy presents unique challenges.
- Mesalazine (5-aminosalicylic acid) is a common treatment for IBD.
- Evaluating the safety of IBD medications during gestation is crucial for maternal and fetal health.
Purpose:
- To assess the pregnancy outcomes of women with inflammatory bowel disease treated with mesalazine.
- To determine the safety profile of mesalazine (Pentasa) exposure during pregnancy.
Summary:
- This study analyzed 11 pregnancies in women treated with mesalazine for inflammatory bowel disease.
- Outcomes included 9 healthy infants, one spontaneous abortion (linked to uterine malformation), and one infant with multiple malformations (mother not exposed during organogenesis).
- The findings suggest a potentially favorable safety profile for mesalazine in pregnancy, but require confirmation due to the small sample size.
Impact:
- Provides preliminary data on mesalazine safety in pregnant IBD patients.
- Informs clinical decision-making regarding IBD treatment during pregnancy.
- Highlights the need for larger, prospective studies to validate mesalazine's safety and efficacy in pregnancy.